Novo Nordisk is suspended from ABPI membership

The Association of the British Pharmaceutical Industry (ABPI) has suspended Novo Nordisk’s membership for two years due to serious breaches of the ABPI Code of Practice. This is after an investigation and appeals process by the Prescription Medicines Code of Practice Authority (PMCPA) found Novo Nordisk in breach. The company will not be able to access the benefits of ABPI membership and will undergo further audits in 2023 and 2024.